Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REV-ERB modulator
- Development stage
- Preclinical
- Lead developer
- Pelagos Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
REV-ERB modulator is a preclinical-stage small molecule agonist of the REV-ERB nuclear receptors (REV-ERBα and REV-ERBβ) being developed by Pelagos Pharma. Functioning as an exercise mimetic, the compound is designed to activate the same beneficial metabolic, mitochondrial, and transcriptional pathways as aerobic exercise. Pelagos Pharma is developing the therapeutic for the treatment of heart failure, obesity, sarcopenia, and cognitive decline (including neurodegenerative diseases such as frontotemporal dementia and Alzheimer's disease). As of 2026, the program is in the lead optimization phase, with development candidate nomination projected for Q3 2027 and IND-enabling studies projected for 2028.
- Other names
- REV-ERB agonist
02
Targets
HDAC3 (Histone Deacetylase 3)NR1D1 (Nuclear receptor subfamily 1 group D member 1)NR1D2 (Nuclear receptor subfamily 1 group D member 2)
Beyond the preview
Go deeper on REV-ERB modulator.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REV-ERB modulator.